J&J Phase 3 seltorexant meets all endpoints; Royalty Pharma holds mid-single-digit royalty

Royalty Pharma plc

J&J's Phase 3 MDD3001 trial of seltorexant met all primary and secondary endpoints in MDD with insomnia.
Seltorexant is a first-in-class orexin-2 receptor antagonist; no approved therapies exist for MDD with insomnia.
Royalty Pharma is entitled to a mid-single-digit royalty on worldwide net sales of seltorexant.
J&J previously estimated non-risk adjusted peak sales potential of $1B–$5B for seltorexant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.